Predictive Value of CEA and ctDNA in Lung Cancer Recurrence

Not yet recruiting

• Conditions: Lung Carcinoma

• Registration Number: NCT07170046
• Lead Sponsor: Guangdong Provincial People's Hospital

Brief Summary

The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.

Detailed Description

This study will collect two groups of cohorts: prospective and retrospective.

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-09-07
• Study First Submitted QC: 2025-09-07
• Last Update Submitted: 2025-09-07
• Study First Posted: 2025-09-12
• Last Update Posted: 2025-09-12
• Study Start: 2025-09-15
• Primary Completion: 2027-08-01
• Study Completion: 2027-08-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Preoperative CEA > 5mg/l
2. MRD testing was conducted before the operation
3. The primary lesion was resected through surgery
4. There should be at least two CEA and MRD follow-up tests within 2 years after the operation
5. Postoperative pathology confirmed it as a malignant lung tumor

Exclusion Criteria

1. Those without available imaging records
2. Patients with a history of malignant tumors within the past five years
3. Patients with secondary lung cancer

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Postoperative tumor recurrence or progression	2 years	If the tumor recurs or progresses within 2 years, it will be marked as 1. If not, it will be marked as 0.